

This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/advances

Design, Synthesis And Biological Evaluation of Soluble 2,5-Diketopiperazines Derivatives As Potential Antifouling Agents

Shengrong Liao, ^a Ying Xu, ^b Yong Tang, ^a Junfeng Wang, ^a Xuefeng Zhou, ^a Liang Xu ^c and Yonghong Liu *^a

- ^a CAS Key Laboratory of Tropical Marine Bio-resources and Ecology/Guangdong Key Laboratory of Marine Materia Medica/Research Center for Marine Microbes, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, PR China; E-Mails: ljrss@126.com (S.L.); 307091847@qq.com (Y.T.); junfeng1982a@163.com (J.W.); xfzhou@scsio.ac.cn (X.Z.)
- ^b Shenzhen Key Laboratory of Marine Bioresource & Eco-environmental Science, Shenzhen Engineering Laboratory for Marine Algal Biotechnology, College of Life Science, Shenzhen University, Shenzhen 518060, PR China; boxuying@szu.edu.cn (Y.X.)
- ^c Enantiotech Corp., Ltd., Zhongshan Torch Hi-Tech, Industrial Development Zone,
 Zhongshan 528437, PR China; xuliang@enantiotech.net (L.X.)
- * Author to whom correspondence should be addressed; E-Mail: yonghongliu@scsio.ac.cn; Tel./Fax: +86-020-8902-3244.

Abstract: A small library of soluble 2,5-diketopiperazine derivatives were designed, synthesized and evaluated as antifouling agents against two species of marine organisms: Balanus amphitrite and Bugula neritina by larval attachment assay. The results showed that different derivatives had different antifouling activities. Among these compounds, **3a** (EC₅₀ = 2.5 μ g•mL⁻¹), **3b** (EC₅₀ = 3.2 μ g•mL⁻¹) and **3d** (EC₅₀ = 1.6 μ g•mL⁻¹) had strong activities, and 2d (EC₅₀ = 20.5 μ g•mL⁻¹), 3l (EC₅₀ = 25.0 $\mu g \cdot mL^{-1}$) and **3m** (EC₅₀ = 18.5 $\mu g \cdot mL^{-1}$) had moderate activities against *Balanus amphitrite*, but other compounds had no activities. Differently, compounds **3d** (EC₅₀ = 3.1 μ g•mL⁻¹) and **3i** (EC₅₀ = 2.3 μ g•mL⁻¹) exhibited strong activities, and **3a** (EC₅₀ = 11.3 μ g•mL⁻¹) and **3c** (EC₅₀ = 17.2 μ g•mL⁻¹) showed moderate activities against Bugula neritina, whereas other compounds had no activities. All of the active compounds had stronger antifouling activities than those of the natural product cyclo-(L-Phe-L-Pro). Compound 3d could be a new template molecule for further development as an antifouling agent because of its strong inhibitory activities against both species of fouling organisms with low or no toxicity to the environment.

1. Introduction

It is well known that biofouling has seriously negative influence on marine-related activities, and a number of effective metal-based (such as cupper(I) compounds and organotins) polymer antifouling coatings have been used to inhibit the attachment of marine organisms (*e.g. Barnacle, Bugula neritina, Mussel*, and *Seaweed*) for a long time ¹. However due to their high toxicity to the environment, they were banned or reduced to use by IMO (International Maritime Organization) in recent years ^{2, 3}, thus new methods for developing environmentally friendly antifoulants should be explored urgently. Although a few papers ^{2, 4} recently reviewed that natural products showed patency as antifoulants with low or even no harm to the environment, yet it might be a dilemma because of their difficult availability ⁵. Fortunately, this problem might be solved *via* the synthesis or optimization of the active natural products which are used as the lead compounds ⁶⁻¹⁰.



Fig. 1. 2,5-Diketopiperazine and its marine natural products or synthetic derivatives.

2,5-Diketopiperazine derivatives (Fig. 1) are not only a class of naturally occurring privileged structures from fungi, bacteria, the plant kingdom, and mammals, but they also have several characteristics that make them attractive scaffolds for drug discovery ^{11, 12}. Several previous articles showed that cyclo-(L-Phe-L-Pro) (Fig. 1) or its homologues which were isolated from marine-derived fungi had moderate activities to inhibit the settlement of barnacles^{13, 14}, and some other modified 2.5-diketopiperazine derivatives (Fig. 1) also showed effective antifouling activities to these sessile marine organisms ¹⁵. These results indicate that the small molecule 2,5-diketopiperazine will be a suitable scaffold for further development in search for high potential antifouling agents. On the other hand, 2,5-diketopiperazine derivatives which have no other substituent on the amide nitrogen atoms except the hydrogen atoms, especially for those with their aromatic groups substituted at 3 and/or 6-positions on its skeleton, show poor solubility because of the existence of intermolecular hydrogen bonds and π - π stacking ^{16, 17}, thus result in negative impacts on their antifouling activity ¹⁸. Therefore, in the present paper, a small library of soluble 2,5-diketopiperazine derivatives, with the hydrogen atoms on the amides replaced by an acetyl group or/and an allyl group, were designed and synthesized (Fig. 2) and their antifouling activities against two species of marine fouling organisms Balanus amphitrite and Bugular neritina, were evaluated aiming to discover more effective 2,5-diketopiperazine derivatives that can be used as environmentally friendly antifouling agents.



Fig. 2. Designing of 2,5-diketopiperazine derivatives used as antifouling agents.

2. Results and Discussion

2.1. Synthesis of 2,5-Diketopiperazine Derivatives

According to our previous study ¹⁶, the synthesis of 2,5-diketopiperazine derivatives was as follows: 1,4-diacetyl-2,5-diketopiperazine and aromatic aldehydes were stirred with Cs₂CO₃ in N,N-dimethylformamide (DMF) at room temperature to yield compound **1**, which was then kept together with allyl bromide and K₂CO₃ in DMF to get compound **2**, and the final compound **3** was obtained by mixing compound **2**, aromatic aldehydes, and Cs₂CO₃ in DMF at atmosphere until the reaction was completed (Scheme 1). Among all the derivatives, compounds **1a-b**, **1d**, **2a-b**, **2d**, **3a-b**, **3e**, and **3h-i** were synthesized in our previous article ¹⁶ and were screened directly to their antifouling activities, and other compounds were synthesized for the first time

RSC Advances Accepted Manuscript

in the present paper. Compound **1** can be easily dissolved in dimethylsulfoxide (DMSO), DMF and, but has low solubility in ethyl acetate (AcOEt), dichloromethane (DCM), chloroform, methanol (MeOH), ethanol (EtOH), *etc.* Compounds **2** and **3** can be dissolved in all of the above solvents.



Scheme 1. Synthesis of 2,5-diketopiperazine derivatives

Regents and conditions: i. 1,4-diacetyl-2,5-diketopiperazine (1.5 equiv.), aromatic aldehyde (1.0 equiv.), Cs₂CO₃ (1.5 equiv.), DMF, rt; ii. allyl bromide (1.2 equiv.), K₂CO₃ (2.0 equiv.), DMF, rt; iii. aromatic aldehyde (1.2 equiv.), Cs₂CO₃ (1.5 equiv.), DMF, rt.

2.2. Antifouling activity

2.2.1 Anti-Attachment Activity of 2,5-Diketopiperazine Derivatives Against *Balanus Amphitrite*.

Although a few researchers suggested that an antifouling compound with an EC₅₀ value less than 5.0 μ g•mL⁻¹ could be considered as a candidate ⁴, in this study, each sample with a concentration of 25.0 μ g•mL⁻¹, was preliminary screened in anti-larval settlement assays ^{19, 20}. As a consequence of the experiments, only these compounds

which had obvious inhibitory activities at this concentration would be selected for further studies. Since the 2,5-diketopiperazine derivatives with no substituent on the amide nitrogen atoms usually have poor solubility, four derivatives were designed and synthesized by introducing some aromatic aldehydes with different electrical properties at 3-positions and an acetyl group at 1-position on the 2,5-diketopiperazine scaffold. Among these derivatives, compound **1a** contains a phenyl (Ph) group, **1b** contains a 3-BrPh group, 1c contains an electron-withdrawing 3-NO₂Ph group, and 1d contains an electron-donating 2-OMePh group, respectively. The antifouling results showed that these derivatives had no activity to inhibit the larval attachment of *Balanus amphitrite* (Table 1). So another four derivatives (2a, 2b, 2c, and 2d) with an allyl group on the other nitrogen atom were synthesized, and the anti-attachment assays showed that compounds 2a, 2b, and 2c still had no inhibitory activities, whereas surprisingly, compound 2d (EC₅₀ = 20.5 μ g•mL⁻¹) displayed a little stronger activity than that of cyclo-(*L*-Phe-*L*-Pro) (EC₅₀ = 68.6 μ g•mL⁻¹) (see refs¹³ and ¹⁴), which indicated that 2-OMe might be an optimal moiety and beneficial to its antifouling ability. As the chloride atom is common in a large number of secondary metabolites and plays an important role in the bioactivity ^{21, 22}, so compound **2d** was selected as a template molecule, and other aromatic aldehydes possessing one or two chloride atoms were chosen to be another substituting unit on 6-position of the 2,5-diketopiperazine scaffold, thus six soluble 2,5-diketopiperazine derivatives (**3b-g**), combined with one derivative (3a) modified by a benzaldehyde group, were designed and synthesized. Their antifouling results against *Balanus amphitrite* are shown in Table 1. From Table

1, we could see that compound **3a** ($EC_{50} = 2.5 \ \mu g \cdot mL^{-1}$) had strong activity, which was the same as to compounds **3b** ($EC_{50} = 3.2 \ \mu g \cdot mL^{-1}$) and **3d** ($EC_{50} = 1.6 \ \mu g \cdot mL^{-1}$), and there were no larval death even at the concentration of 25.0 $\mu g \cdot mL^{-1}$ and the lowest LC_{50}/EC_{50} ratio of these three compounds was higher than 5.0, indicating that these derivatives were non-toxic or low-toxic ¹⁹. While compounds **3c** with a 3-CIPh group, **3e** with a 3,4-CIPh group, **3f** with a 3,5-CIPh group, and **3g** with a 2-CI-5-CF₃Ph group had no activity, which implied the number of chloride atoms and the substitutive position on the phenyl ring were both important to their antifouling activities ²³.

In order to obtain more information of antifouling abilities about other substituted aromatic aldehyde, another six soluble derivatives (**3h-m**) were also synthesized, and their antifouling abilities to inhibit the larval attachment of *Balanus amphitrite* were determined, and the results showed that compounds **3h-k** had no activities except **3l** and **3m**, which had moderate antifouling activities with the EC₅₀ values of 25.0 and 18.5 µg•mL⁻¹, respectively (Table 1). These results demonstrated that 3-NO₂Ph might be another effective group used as a derived molecule in exploring antifouling agents, nevertheless, in comparison to the former derivatives which contained one 2-OMePh group, their antifouling effectiveness is weaker.

Table 1. Anti-settlement activities of the synthetic 2,5-diketopiperazine derivatives and

| Compounds | Balanus amphitrite | | |
|---------------------------------------|-------------------------------------|----------------------------------|-------------------------------------|
| | $EC_{50} (\mu g \cdot mL^{-1})^{a}$ | $LC_{50}(\mu g \cdot mL^{-1})^b$ | LC ₅₀ / EC ₅₀ |
| cyclo-(<i>L</i> -Phe- <i>L</i> -Pro) | >25 | >25 | |
| | 68.6 | 115 | $=1.7^{d}$ |
| 1a | >25 | >25 | - |
| 1b | >25 | >25 | - |
| 1c | >25 | >25 | - |
| 1d | >25 | >25 | - |
| 2a | >25 | >25 | - |
| 2b | >25 | >25 | - |
| 2c | >25 | >25 | - |
| 2d | 20.5 ± 1.8^{e} | >25 | >1.2 |
| 3a | 2.5±0.03 | >25 | >10.0 |
| 3b | 3.2±0.4 | >25 | >7.8 |
| 3c | >25 | >25 | - |
| 3d | 1.6 ± 0.01 | >25 | >15.6 |
| 3e | >25 | >25 | - |
| 3f | >25 | >25 | - |
| 3g | >25 | >25 | - |
| 3h | >25 | >25 | - |
| 3i | >25 | >25 | - |
| 3ј | >25 | >25 | - |
| 3k | >25 | >25 | - |
| 31 | 25.0±2.5 | >25 | =1.0 |
| 3m | 18.5±1.3 | >25 | >1.4 |

compound cyclo-(L-Phe-L-Pro) against Balanus amphitrite.

^{*a*} EC₅₀: The concentration of a compound that inhibited larval attachment by 50% in comparison with the control; ^{*b*} LC₅₀: The concentration that caused 50% larval mortality in testing wells in comparison with the control; ^{*c*} -: Undetectable; ^{*d*} refs ^{13, 14}; ^{*e*} The concentrations (EC₅₀ values) are denoted as the means \pm SD (for n = 3).

RSC Advances Accepted Manuscript

2.2.2. Anti-Settlement Activity of 2,5-Diketopiperazine Derivatives Against Bugula

Neritina

Table 2. Anti-settlement activities of the synthetic 2,5-diketopiperazine derivatives and

| Compounds | Bugula neritina | | | |
|---------------------------------------|-------------------------------------|----------------------------------|-------------------------------------|--|
| | $EC_{50} (\mu g \cdot mL^{-1})^{a}$ | $LC_{50}(\mu g \cdot mL^{-1})^b$ | LC ₅₀ / EC ₅₀ | |
| cyclo-(<i>L</i> -Phe- <i>L</i> -Pro) | >25 | >25 | | |
| | 70.4 | >200 | $>2.8^{d}$ | |
| 1 a | >25 | >25 | - | |
| 1b | >25 | >25 | - | |
| 1c | >25 | >25 | - | |
| 1d | >25 | >25 | - | |
| 2a | >25 | >25 | - | |
| 2b | >25 | >25 | - | |
| 2c | >25 | >25 | - | |
| 2d | >25 | >25 | - | |
| 3a | 11.3 ± 0.9^{e} | >25 | >2.2 | |
| 3b | >25 | >25 | - | |
| 3c | 17.2±0.8 | >25 | >1.5 | |
| 3d | 3.1±0.5 | >25 | >8.1 | |
| 3e | >25 | >25 | - | |
| 3f | >25 | >25 | - | |
| 3g | >25 | >25 | - | |
| 3h | >25 | >25 | - | |
| 3i | 2.3±0.1 | >25 | >10.9 | |
| 3ј | >25 | >25 | - | |
| 3k | >25 | >25 | - | |
| 31 | >25 | >25 | - | |
| 3m | >25 | >25 | - | |

compound cyclo-(L-Phe-L-Pro) against Bugula neritina.

^{*a*} EC₅₀: The concentration of a compound that inhibited larval attachment by 50% in comparison with the control; ^{*b*} LC₅₀: The concentration that caused 50% larval mortality in testing wells in comparison with the control; ^{*c*} -: Undetectable; ^{*d*} ref ¹³; ^{*e*} The concentrations (EC₅₀ values) are denoted as the means \pm SD (for n = 3).

The antifouling abilities to inhibit the settlement of *Bugula neritina* by the above synthesized compounds were also investigated and the results are listed in Table 2. Unlike their inhibition of the larval settlement of *Balanus amphitrite*, compound **3d** ($EC_{50} = 3.1 \ \mu g \cdot m L^{-1}$) had strong abilities to inhibit the attachment of *Bugula neritina*, however compound **3b** had no activity. We were pleased to find that compound **3i** exhibited strong activity with an EC_{50} value of 2.3 $\mu g \cdot m L^{-1}$, and compounds **3a** ($EC_{50} = 11.3 \ \mu g \cdot m L^{-1}$) and **3c** ($EC_{50} = 17.2 \ \mu g \cdot m L^{-1}$) showed moderate activity against the attachment of *Bugula neritin*. Other compounds had no activity at a concentration of 25 $\mu g \cdot m L^{-1}$. Similar to the toxicity of compounds **3a**, **3b** and **3d** against *Balanus amphitrite*, there were no *Bugula neritina* death and the lowest LC_{50}/EC_{50} ratio was more than 5.0 which indicated that compounds **3d** and **3i** were non-toxic or low-toxic ¹⁹. These results revealed that different marine organism species might show different sensitivities to their inhibitors and the activity and toxicity of the active derivatives might be combined in order to achieve better antifouling performance.

2.3 Compound 3d Hold Promise As Environmentally Friendly Antifouling Agent

In a more intuitive comparison study, the EC_{50} values of the active synthesized compounds and cyclo-(*L*-Phe-*L*-Pro) to inhibit the larval attachment of *Balanus amphitrite* and *Bugula neritina* are shown in Fig. 3 and 4. From Fig. 3 and 4, it was found that all the active synthesized compounds had stronger inhibitory activity than that of cyclo-(*L*-Phe-*L*-Pro). These might be due to the higher liposolubility of the derivatives than that of cyclo-(*L*-Phe-*L*-Pro), thus resulted in the penetration of the

former through tissues and reached the target more easily 15,24 . Among all the active compounds, compound **3d** had strong antifouling activities against both of the marine organisms as well as with low or no toxicity, and would be a new chemical template for the further development as environmentally friendly antifouling agent.



Fig. 3. A comparison for the effect of the active derivatives against *Balanus amphitrite*. EC₅₀ values of compounds **2d**, **3a**, **3b**, **3d**, **3m**, **3l**, and cyclo-(*L*-Phe-*L*-Pro) against *Banalus amphitrite* were 20.5±1.8, 2.5±0.03, 3.2±0.4, 1.6±0.01, 18.5±1.3, 25.0±2.5, and 68.6 ^{13, 14} (µg•mL⁻¹), respectively, and the concentrations (EC₅₀ values) are denoted as the means ± SD (for n = 3).



Fig. 4. A comparison for the effect of the active derivatives against *Bugula neritina*. EC₅₀ values of compounds **3a**, **3c**, **3d**, **3i**, and cyclo-(*L*-Phe-*L*-Pro) against *Bugula neritina* were 11.3±0.9, 17.2±0.8, 3.1±0.5, 2.3±0.1, and 70.4¹³ (μ g•mL⁻¹), respectively, and the concentrations (EC₅₀ values) are denoted as the means ± SD (for n = 3).

3. Conclusions

Inspired by the structure-activity relationships of the natural product cyclo-(*L*-Phe-*L*-Pro) and the synthesized compound 5-bromodipodazine, a small library of soluble 2,5-diketopiperazine derivatives were designed, synthesized and evaluated for their antifouling activities against *Balanus amphitrite* and *Bugular neritina*. The results showed that three compounds (**3a**, **3b**, and **3d**) had strong activities against *Balanus amphitrite*, and two compounds (**3d** and **3i**) exhibited strong activities against *Bugula neritina*, in which compound **3d** had strong activities against

both of the marine organisms, and all these active compounds were low-toxic or non-toxic. These results confirmed that 2,5-diketopiperazine is a useful scaffold in search for effective antifouling agents, meanwhile, they also offer an example to illustrate that it is feasible that natural products or their optimized derivatives can indeed be used as antifouling candidates with low or no toxicity to the environment. Furthermore, compound **3d** may be a new template molecule for further development as antifouling agents.

4. Experimental Section

4.1. Chemistry

Melting points (m.p.) were determined by using a SRSO-ptiMelt automated melting point instrument without correction. The NMR spectra were recorded on a Bruker AC 500 NMR spectrometer with TMS as an internal standard. HR-ESI-MS data were measured on AQUITY UPLC/Q-TOF mass spectrometer. IR spectra were recorded on a Shimadzu IR Affinity-1 fourier transform infrared spectrometer. Materials for column chromatography were silica gel (200–300 mesh, Qingdao Marine Chemical Factory, Qingdao, China). All solvents were analytical grade. DMF was dried in CaH₂ and distilled. 1,4-diacetyl-2,5-diketopiperazine was purchased from Sigma Aldrich, and others from Aladdin. All chemicals were used without further purification. Compounds **1a-b**, **1d**, **2a-b**, **2d**, **3b-c**, **3e**, and **3h-i** were synthesized and characterized according to our previous article ¹⁶, and other compounds were synthesized as follows:

4.1.1. Synthesis of compound 1-acetyl-3-(3-nitrobenzylidene)piperazine-2,5-dione (1c)

 Cs_2CO_3 (1.5 equiv., 0.51 mmol, 166.0 mg) was added into the solution containing 1-acetyl-3-(3-nitrobenzylidene)piperazine-2,5-dione (1.5 equiv., 0.51 mol, 100.0 mg) and 3-nitrobenzaldehyde (1.0 equiv., 0.34 mmol, 51.0 mg) in dry DMF (2 mL), and the mixture was stirred at room temperature for about 5 hours. After the reaction was completed, the mixture was poured into crashed ice and the solid was filtered, washed with water for three times and dried. The target compound **1c** was obtained as white solids with a yield of 82%. m.p. 197 – 200 °C, FT-IR (neat, cm⁻¹): 3176, 1689, 1637, 1525, 1348, 1261, 1207, 796, 729; ¹H NMR (500 MHz, DMSO-*d*₆) δ = 10.72 (s, 1H, N–H), 8.37 (s, 1H, Ar–H), 8.17 (d, *J* =10.0 Hz, 1H, Ar–H), 7.94 (d, *J* =10.0 Hz, 1H, Ar–H), 7.70 (t, *J* =10.0 Hz, 1H, Ar–H), 7.03 (s, 1H, =CH–H), 4.38 (s, 2H, –CH₂–), 2.51 (s, 3H, –CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆) δ = 171.92, 164.34, 160.97, 147.90, 136.14, 134.79, 130.01, 129.02, 123.90, 122.84, 115,54, 45.87, 26.83; HRMS (ESI) (*m*/*z*) [M+H]⁺ for (C₁₃H₁₂N₃O₅) calculated 290.0771 found 290.0767; [M+Na]⁺ for (C₁₃H₁₁N₃NaO₅) calculated 312.0591 found 312.0590.

4.1.2. Synthesis of compound

1-acetyl-4-allyl-3-(3-nitrobenzylidene)piperazine-2,5-dione (2c)

 K_2CO_3 (2 equiv., 97 mg) was added into the solution containing compound 1c (1 equiv., 100mg, 0.35 mmol) and allyl bromide (1.2 equiv., 0.42 mmol, 0.35 mL) in dry DMF (2 mL), and the mixture was stirred at room temperature overnight. After the reaction was completed, the mixture was poured into crashed ice and the solid was filtered, washed with water for three times and purified by silica gel chromatography. The target compound 2c was obtained as white solids with a yield of 55%. m.p. 80 – 83

RSC Advances Accepted Manuscript

°C, FT-IR (neat, cm⁻¹): 1691, 1627, 1531, 1350, 1286, 1263, 1184; ¹H NMR (500 MHz, CDCl₃) δ = 8.23 (d, *J* =10.0 Hz, 1H, Ar–H), 8.17 (s, 1H, Ar–H), 7.67–7.61 (m, 2H, Ar–H), 7.30 (s, 1H, =C–H), 5.54–5.46 (m, 1H, =C–H), 5.03 (d, *J* =10.0 Hz, 1H, =CH–H), 4.69 (d, *J* = 20.0 Hz, 1H, =CH–H), 4.56 (s, 2H, –CH₂–), 4.07 (d, *J* = 10.0 Hz, 2H, –CH₂–), 2.63 (s, 3H, –CH₃); ¹³C NMR (125 MHz, CDCl₃) δ = 171.17, 164.54, 163.47, 148.29, 134.88, 134.55, 131.64, 130.67, 129.80, 124.13, 124.00, 122.98, 119.16, 46.74, 45.19, 26.72 ppm; HRMS (ESI) (*m*/*z*) [M+H]⁺ for (C₁₆H₁₆N₃O₅) calculated 330.1084 found 330.1082; [M+Na]⁺ for (C₁₆H₁₅N₃NaO₅) calculated 352.0904 found 352.0907.

4.1.3. General procedure for synthesis of compounds 3a, 3d, 3f-g, 3j-m

 Cs_2CO_3 (1.5 equiv.) was added into the solution containing compound 2 (1.0 equiv., 50.0 mg) and aromatic aldehyde (1.2 equiv.) in dry DMF (1.5 mL), and the mixture was stirred at room temperature for about 5 hours. After the reaction was completed, the mixture was slowly poured into water and extracted with AcOEt for three times, and the organic layer was dried, filtered, and purified with silica gel column to afford the target compounds.

4.1.3.1. 1-allyl-3-benzylidene-6-(2-methoxybenzylidene)piperazine-2,5-dione (3a). According to the general procedure, compound 3a was synthesized as a yellow solid with a yield of 56.3%. m.p. 68 – 80 °C, FT-IR (neat, cm⁻¹): 3232, 1676, 1618, 1487,1452 1379, 1354, 1246, 1022, 752; ¹H NMR (500 MHz, CDCl₃) δ = 8.11 (s, 1H, N-H), 7.45–7.43 (m, 4H, Ar–H), 7.35 (t, *J* = 10.0 Hz, 2H, Ar–H), 7.32 (s, 1H, =C–H), 7.22 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.06 (s, 1H, =C–H), 6.98 (t, *J* = 10.0 Hz, 1H, =C–H),

6.92 (d, J = 10.0 Hz, 1H, Ar–H), 5.55–5.51 (m, 1H, =C–H), 5.00 (d, J = 10.0 Hz, 1H, =CH–H), 4.76 (d, J = 20.0 Hz, 1H, =CH–H), 4.24 (d, J = 10.0 Hz, 2H, –CH₂–), 3.85 (s, 3H, –OCH₃); ¹³C NMR (125 MHz, CDCl₃) $\delta = 160.04$, 159.17, 157.30, 132.98, 131.41, 130.51, 130.34, 129.31, 128.67, 128.50, 128.28, 126.10, 122.78, 120.18, 118.33, 118.02, 117.17, 110.59, 55.42, 47.35 ppm; HRMS (ESI) (m/z) [M+H]⁺ for (C₂₂H₂₁N₂O₃) calculated 361.1547 found 361.1551; [M+Na]⁺ for (C₂₂H₂₀N₂NaO₃) calculated 383.1366 found 383.1371.

4.1.3.2.

1-allyl-3-(4-chlorobenzylidene)-6-(2-methoxybenzylidene)piperazine-2,5-dione (3*d*). According to the general procedure, compound 3d was synthesized as a yellow solid with a yield of 62.3%. m.p. 135 – 136 °C, FT-IR (neat, cm⁻¹): 3197, 1681, 1668, 1616, 1489, 1384, 1355, 1323, 1247, 1016, 752; ¹H NMR (500 MHz, CDCl₃) δ = 8.02 (s, 1H, N–H), 7.42 (d, *J* = 10.0 Hz, 2H, Ar–H), 7.38–7.36 (m, 3H, Ar–H), 7.34 (s, 1H, =C–H), 7.22 (d, *J* = 10.0 Hz, 1H, Ar–H), 6.98 (t, *J* = 10.0 Hz, 1H, Ar–H, 1H, =C–H), 6.93 (d, *J* = 5.0 Hz, 1H, Ar–H), 5.57–5.51 (m, 1H, =C–H), 5.01 (d, *J* = 10.0 Hz, 1H, ar–H), 4.23 (s, *J* = 5.0 Hz, 2H, -CH₂–), 3.86 (s, 3H, -OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ = 160.35, 159.04, 157.36, 134.56, 131.42, 131.33, 130.66, 130.37, 129.93, 129.53, 128.12, 126.46, 122.67, 120.23, 118.75, 118.19, 116.01, 110.64, 55.48, 47.41 ppm; HRMS (ESI) (*m/z*) [M+H]⁺ for (C₂₂H₂₀ClN₂O₃) calculated 395.1157 found 395.1153; [M+Na]⁺ for (C₂₂H₁₉ClN₂NaO₃) calculated 417.0972.

RSC Advances Accepted Manuscript

4.1.3.3.

1-allyl-3-(3,5-dichlorobenzylidene)-6-(2-methoxybenzylidene)piperazine-2,5-dione

(3*f*). According to the general procedure, compound 3*f* was synthesized as a yellow solid with a yield of 32.7%. m.p. 186 – 188 °C, FT-IR (neat, cm⁻¹): 3179, 1682, 1666, 1622, 1456, 1355, 1338, 1242, 1022, 754; ¹H NMR (500 MHz, CDCl₃) δ = 8. 33 (s, 1H, N–H), 7.37 (t, *J* = 10.0 Hz, 1H, Ar–H), 7.31 (s, 2H, Ar–H), 7.29 (s, 1H, Ar–H; 1H, =C–H), 7.21 (d, *J* = 5.0 Hz, 1H, Ar–H), 6.99 (t, *J* = 10.0 Hz, 1H, Ar–H), 6.93 (d, *J* = 10.0 Hz, 1H, Ar–H), 6.90 (s, 1H, =C–H), 5.58–5.50 (m, 1H, =C–H), 5.01 (d, *J* = 10.0 Hz, 1H, Ar–H), 4.76 (d, *J* = 15.0 Hz, 1H, =CH–H), 4.23 (d, *J* = 10.0 Hz, 2H, –CH₂–), 3.86 (s, 3H, –OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ = 160.34, 158.57, 157.40, 136.07, 135.95, 131.21, 130.79, 130.37, 128.55, 128.01, 127. 85, 126.79, 122.56, 120.28, 119.31, 118.31, 113.99, 110.68, 55.51, 47.49 ppm; HRMS (ESI) (*m/z*) [M+H]⁺ for (C₂₂H₁₉Cl₂N₂O₃) calculated 429.0767 found 429.0767; [M+Na]⁺ for (C₂₂H₁₈Cl₂N₂NaO₃) calculated 451.0587 found 451.0586.

4.1.3.4.

1-allyl-3-(2-chloro-5-(trifluoromethyl)benzylidene)-6-(2-methoxybenzylidene)piperazi ne-2,5-dione (3g). According to the general procedure, compound **3g** was synthesized as a yellow solid with a yield of 47.9%. m.p. 137 – 138 °C, FT-IR (neat, cm⁻¹): 3180, 1682, 1620, 1489, 1386, 1352, 1321, 1246, 1132, 1122, 1080, 758, 748; ¹H NMR (500 MHz, CDCl₃) δ = 8.15 (s, 1H, N–H), 7.69 (s, 1H, Ar–H), 7.61 (d, *J* = 5.0 Hz, 1H, Ar–H), 7.53 (d, *J* = 5.0 Hz, 1H, Ar–H), 7.37 (t, *J* = 5.0 Hz, 1H, Ar–H), 7.25 (s, 1H, =C–H), 7.21 (d, *J* = 5.0 Hz, 1H, Ar–H), 7.08 (s, 1H, =C–H), 6.99 (t, *J* = 5.0 Hz,

1H, Ar–H), 6.93 (d, J = 10.0 Hz, 1H, Ar–H), 5.58–5.51 (m, 1H, =C–H), 5.01 (d, J = 10.0 Hz, 1H, =CH–H), 4.76 (d, J = 15.0 Hz, 1H, =CH–H), 4.26 (d, J = 5.0 Hz, 2H, –CH₂–), 3.87 (s, 3H, –OCH₃); ¹³C NMR (125 MHz, CDCl₃) $\delta = 160.12$, 158.26, 157.36, 138.14, 132.56, 131.21, 130.97, 130.77, 130.41, 130.02, 129.76, 128.67, 127.77, 126.47 (q, $J_{C-F} = 3.75$ Hz, –CF₃), 122.63, 120.27, 119.37, 118.38, 112.32, 110.68, 55.50, 47.43 ppm; HRMS (ESI) (m/z) [M+H]⁺ for (C₂₃H₁₉ClF₃N₂O₃) calculated 463.1031 found 463.1037; [M+Na]⁺ for (C₂₃H₁₈ClF₃N₂NaO₃) calculated 485.0850 found 485.0856.

4.1.3.5. 1-allyl-6-(3-bromobenzylidene)-3-(3-methylbenzylidene)piperazine-2,5-dione (3j). According to the general procedure, compound 3j was synthesized as a yellow solid with a yield of 56.0%. m.p. 111 – 113 °C, FT-IR (neat, cm⁻¹): 3197, 1680, 1614, 1456, 1353, 1332, 1238, 923, 777; ¹H NMR (500 MHz, CDCl₃) δ = 8.17 (s, 1H, N–H), 7.48 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.44 (s, 1H, Ar–H), 7.33 (t, *J* = 10.0 Hz, 1H, Ar–H), 7.27 (t, *J* = 5.0 Hz, 1H, Ar–H), 7.23 (d, *J* = 5.0 Hz, 3H, Ar–H), 7.16 (d, *J* = 5.0 Hz, 1H, Ar–H, 1H, =C–H), 7.06 (s, 1H, =CH–H), 5.57–5.50 (m, 1H, =C–H), 5.04 (d, *J* = 10.0 Hz, 1H, =CH–H), 4.78 (d, *J* = 15.0 Hz, 1H, =CH–H), 4.26 (d, *J* = 5.0 Hz, 2H, –CH₂–), 2.38 (s, 3H, –CH₃); ¹³C NMR (125 MHz, CDCl₃) δ = 159.50, 159.35, 139.20, 136.06, 132.68, 132.01, 131.69, 131.22, 129.89, 129.77, 129.27, 129.24, 129.08, 127.82, 125.58, 125.52, 122.52, 119.86, 118.44, 118.22, 48.05, 21.43 ppm; pm; HRMS (ESI) (*m*/z) [M+H]⁺ for (C₂₂H₂₀BrN₂O₂) calculated 423.0703 found 423.0709; [M+Na]⁺ for (C₂₂H₁₉BrN₂NaO₂) calculated 445.0522 found 445.0525.

RSC Advances Accepted Manuscript

4.1.3.6.

1-allyl-6-(3-bromobenzylidene)-3-(2,3,4-trimethoxybenzylidene)piperazine-2,5-dione (*3k*). According to the general procedure, compound **3k** was synthesized as a yellow solid with a yield of 51.7%. m.p. 146 – 148 °C, FT-IR (neat, cm⁻¹): 3230, 1680, 1665, 1614, 1525, 1348, 1330, 1236, 1024, 921, 777, 680; ¹H NMR (500 MHz, CDCl₃) δ = 9.34 (s, 1H, N–H), 7.45 (d, *J* = 5.0 Hz, 1H, Ar–H), 7.42 (s, 1H, Ar–H), 7.25 (d, *J* = 5.0 Hz, 1H, Ar–H), 7.42 (s, 1H, Ar–H), 7.25 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.22 (d, *J* = 5.0 Hz, 1H, Ar–H), 7.16 (s, 1H, =C–H), 7.04 (d, *J* = 10.0 Hz, 1H, Ar–H), 6.95 (s, 1H, =C–H), 6.75 (d, *J* = 10.0 Hz, 1H, Ar–H), 5.59–5.52 (m, 1H, =C–H), 5.04 (d, *J* = 10.0 Hz, 1H, =CH–H), 4.79 (d, *J* = 15.0 Hz, 1H, =CH–H), 4.26 (d, *J* = 5.0 Hz, 2H, –CH₂–), 3.92 (s, 3H, –OCH₃), 3.90 (s, 6H, –OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ = 160.01, 159.24, 154.74, 150.71, 142.79, 136.30, 131.98, 131.49, 131.43, 129.83, 129.71, 127.83, 126.72, 124.74, 122.44, 120.02, 119.29, 118.10, 115.44, 108.43, 61.93, 61.22, 56.10, 48.12 ppm; pm; HRMS (ESI) (*m/z*) [M+H]⁺ for (C₂₄H₂₄BrN₂O₅) calculated 499.0863 found 499.0870; [M+Na]⁺ for (C₂₄H₂₃BrN₂NaO₅) calculated 521.0683 found 521.0690.

4.1.3.7. *1-allyl-3-(3-methylbenzylidene)-6-(3-nitrobenzylidene)piperazine-2,5-dione* (31). According to the general procedure, compound 31 was synthesized as a yellow solid with a yield of 62.0%. m.p. 145 – 146 °C, FT-IR (neat, cm⁻¹): 3219, 1682, 1620, 1494, 1465, 1410, 1373, 1280, 1097, 906, 729; ¹H NMR (500 MHz, CDCl₃) δ = 8.21 (d, *J* = 10.0 Hz, 1H, Ar–H), 8.15 (s, 2H, Ar–H), 7.64–7.58 (m, 2H, Ar–H), 7.35 (t, *J* = 10.0 Hz, 1H, Ar–H), 7.23 (s, 1H, Ar–H; 1H, =C–H), 7.19 (d, *J* = 10.0 Hz, 1H, Ar–H), 5.55–5.47 (m, 1H, =C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 1H, =C–H), 5.55–5.47 (m, 1H, =C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 1H, =C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 1H, =C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 1H, =C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 1H, =C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 2H, 2C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 2H, 2C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 2H, 2C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 2H, 2C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 2H, 2C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, Ar–H), 7.10 (s, 2H, 2C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, 2C–H), 5.55–5.47 (m, 2H, 2C–H), 5.03 (d, *J* = 10.0 Hz, 1H, 2C–H), 5.55–5.47 (m, 2H, 2C–H), 5.55

=CH–H), 4.73 (d, J = 20.0 Hz, 1H, =CH–H), 4.25 (d, J = 5.0 Hz, 2H, –CH₂–), 2.39 (s, 3H, –CH₃); ¹³C NMR (125 MHz, CDCl₃) $\delta = 159.17$, 158.98, 148.07, 139.33, 135.89, 134.89, 132.57, 131.01, 130.33, 129.94, 129.41, 129.37, 129.08, 125.56, 125.25, 123.98, 123.28, 118.96, 118.31, 118.20, 48.12, 21.45 ppm; HRMS (ESI) (*m/z*) [M+H]⁺ for (C₂₂H₂₀N₃O₄) calculated 390.1448 found 390.1455; [M+Na]⁺ for (C₂₂H₁₉N₃NaO₄) calculated 412.1268 found 412.1278.

4.1.3.8. *1-allyl-3-(3-chlorobenzylidene)-6-(3-nitrobenzylidene)piperazine-2,5-dione* (*3m*). According to the general procedure, compound **3m** was synthesized as a yellow solid with a yield of 48.6%. m.p. 172 – 173 °C, FT-IR (neat, cm⁻¹): 3174, 1682, 1666, 1616, 1526, 1375, 1343, 1318, 731, 690; ¹H NMR (500 MHz, CDCl₃) δ = 8.40 (s, 1H, N–H), 8.22 (d, *J* = 10.0 Hz, 1H, Ar–H), 8.15 (s, 1H, Ar–H), 7.63–7.59 (m, 2H, Ar–H), 7.43 (s, 1H, Ar–H), 7.39 (t, *J* = 10.0 Hz, 1H, Ar–H), 7.32 (t, *J* = 10.0 Hz, 2H, Ar–H), 7.22 (s, 1H, =C–H), 7.05 (s, 1H, =C–H), 5.53–5.47 (m, 1H, =C–H), 5.04 (d, *J* = 10.0 Hz, 1H, =CH–H), 4.73 (d, *J* = 20.0 Hz, 1H, =CH–H), 4.23 (d, *J* = 5.0 Hz, 2H, –CH₂–); ¹³C NMR (125 MHz, CDCl₃) δ = 159.23, 158.85, 148.09, 135.74, 135.37, 134.88, 134.47, 130.87, 130.65, 130.07, 129.48, 129.01, 128.50, 126.74, 126.38, 123.98, 123.39, 118.73, 118.45, 117.03, 48.18 ppm; HRMS (ESI) (*m*/*z*) [M+H]⁺ for (C₂₁H₁₇ClN₃O₄) calculated 410.0902 found 410.0903; [M+Na]⁺ for (C₂₁H₁₆ClN₃NaO₄) calculated 432.0722.

4.2 Anti-larval settlement assay

Adults of Balanus amphitrite were collected from Pak Sha Wan, Hong Kong (22°19'N, 114°16'E) while adults of Bugula neritina were collected from submerged rafts at fish farms in Yung Shue O, Hong Kong (22°24'N, 114°21'E). The settlement assays were carried out according to the method described by a previous study ²⁰: Compounds dissolved in DMSO were diluted to a final concentration of 25.0 ug•ml⁻¹ with filtered seawater (FSW) for a preliminary anti-larval settlement activity test. The synthetic compounds were serial diluted with FSW to 25.0, 12.5, 6.25, 3.125, and 1.06 µg•ml⁻¹ for further bioassay. About 15–20 competent larvae were gently transferred into each well containing 1 ml of the testing solution, which was replaced by 0.1% DMSO in FSW in the negative controls. The plates for Balanus amphitirte were incubated for 48 h at 25 °C while those for *Bugula neritina* were incubated for 24 h at 25 °C. The effects of the compounds on larval settlement were determined by observing the plates under a dissecting microscope to check for (1) settled larvae, (2) swimming larvae, and (3) dead larvae. The number of settled larvae was expressed as a percentage of the total number of larvae per well.

 EC_{50} was calculated as the concentration at which 50% of the larval population was inhibited from settling, compared with that in the negative control while LC_{50} was calculated as the concentration at which 50% of the larval population died. Each compound was tested using three different batches of larvae to determine the mean and standard deviation (SD) of the EC_{50} and LC_{50} values.

Acknowledgments

This work was supported by a grant from National Natural Science Foundation of China

(21402218), the foundation of the innovation team of Zhongshan City, the National Key

Basic Research Program of China (973 Project, 2011CB915503), the National High

Technology Research and Development Program (863 Program, 2012AA092104), the

Strategic Priority Research Program of the Chinese Academy of Sciences

(XDA11030403), Guangdong Marine Economic Development and Innovation of

Regional Demonstration Project (GD2012-D01-001).

Conflict of Interests

The authors declare no conflict of interests.

References and Notes

- 1. G. D. Bixler and B. Bhushan, *Philos T R Soc A*, 2012, **370**, 2381-2417.
- 2. N. Fusetani, *Nat Prod Rep*, 2011, **28**, 400-410.
- 3. Y. T. Cui, S. L. Teo, W. Leong and C. L. Chai, *Int J Mol Sci*, 2014, 15, 9255-9284.
- 4. P. Y. Qian, Y. Xu and N. Fusetani, *Biofouling*, 2010, **26**, 223-234.
- 5. C. M. Kirschner and A. B. Brennan, *Annual Review of Materials Research, Vol* 42, 2012, **42**, 211-229.
- 6. P. Y. Qian, Z. Li, Y. Xu, Y. Li and N. Fusetani, *Biofouling*, 2015, **31**, 101-122.
- V. Piazza, I. Dragic, K. Sepcic, M. Faimali, F. Garaventa, T. Turk and S. Berne, Mar Drugs, 2014, 12, 1959-1976.
- 8. D. Blihoghe, E. Manzo, A. Villela, A. Cutignano, G. Picariello, M. Faimali and A. Fontana, *Biofouling*, 2011, **27**, 99-109.
- 9. S. Kantheti, R. Narayan and K. V. S. N. Raju, *Rsc Adv*, 2015, 5, 3687-3708.
- 10. M. S. Majik, S. Tilvi, S. Mascarenhas, V. Kumar, A. Chatterjee and M. Banerjee, *Rsc Adv*, 2014, 4, 28259-28264.
- 11. Y. Wang, P. Wang, H. Ma and W. Zhu, *Expert Opin Ther Pat*, 2013, 23, 1415-1433.
- 12. A. D. Borthwick, Chem Rev, 2012, 112, 3641-3716.
- S.-H. Qi, Y. Xu, H.-R. Xiong, P.-Y. Qian and S. Zhang, World J Microbiol Biotechnol, 2009, 25, 399-406.

- 14. X. Li, S. Dobretsov, Y. Xu, X. Xiao, O. S. Hung and P. Y. Qian, *Biofouling*, 2006, **22**, 201-208.
- M. Sjogren, A. L. Johnson, E. Hedner, M. Dahlstrom, U. Goransson, H. Shirani, J. Bergman, P. R. Jonsson and L. Bohlin, *Peptides*, 2006, 27, 2058-2064.
- 16. S. Liao, X. Qin, D. Li, Z. Tu, J. Li, X. Zhou, J. Wang, B. Yang, X. Lin, J. Liu, X. Yang and Y. Liu, *Eur J Med Chem*, 2014, **83**, 236-244.
- 17. S. Ando, A. L. Grote and K. Koide, *J Org Chem*, 2011, **76**, 1155-1158.
- 18. W. A. Loughlin, R. L. Marshall, A. Carreiro and K. E. Elson, *Bioorg Med Chem Lett*, 2000, **10**, 91-94.
- 19. X. Zhou, Z. Zhang, Y. Xu, C. Jin, H. He, X. Hao and P. Y. Qian, *Biofouling*, 2009, **25**, 69-76.
- 20. Y. X. Li, F. Y. Zhang, Y. Xu, K. Matsumura, Z. Han, L. L. Liu, W. H. Lin, Y. X. Jia and P. Y. Qian, *Biofouling*, 2012, **28**, 857-864.
- B. G. Wang, J. B. Gloer, N. Y. Ji and J. C. Zhao, *Chem Rev*, 2013, 113, 3632-3685.
- 22. M. T. Cabrita, C. Vale and A. P. Rauter, *Mar Drugs*, 2010, **8**, 2301-2317.
- 23. B. M. Xi, Z. Z. Jiang, J. W. Zou, P. Z. Ni and W. H. Chen, *Bioorg Med Chem*, 2011, **19**, 783-788.
- 24. Y. Xu, H. P. He, S. Schulz, X. Liu, N. Fusetani, H. R. Xiong, X. Xiao and P. Y. Qian, *Bioresource Technol*, 2010, **101**, 1331-1336.